RCEL

AVITA Medical, Inc. [RCEL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RCEL Stock Summary

Top 10 Correlated ETFs

RCEL


Top 10 Correlated Stocks

RCEL


In the News

04:30 29 Sep 2023 RCEL

AVITA Medical to Present at the Cantor Global Healthcare Conference

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time.

06:45 29 Sep 2023 RCEL

AVITA Medical to Participate in Upcoming Investor Conferences

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management team will participate in the following upcoming investor conferences:

10:47 29 Sep 2023 RCEL

AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Brooks O'Neil - Lake Street Capital Markets Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Ross Osborne - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. Second Quarter 2023 Earnings Call.

08:54 29 Sep 2023 RCEL

AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair

AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force positioned to capitalize.

08:08 29 Sep 2023 RCEL

Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?

Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

02:25 29 Sep 2023 RCEL

Why Shares of Avita Medical Are Soaring Thursday

Avita specializes in devices and therapies to restore skin growth. The FDA's nod means that the company's Recell system can expand beyond applications for burn patients.

12:23 29 Sep 2023 RCEL

AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System

AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.

10:08 29 Sep 2023 RCEL

AVITA Medical, Inc. (RCEL) Q1 2023 Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Phillip Dantoin - Piper Sandler Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2023 Earnings Conference Call.

09:55 29 Sep 2023 RCEL

Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

04:30 29 Sep 2023 RCEL

AVITA Medical to Announce First Quarter 2023 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, April 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 11, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 12, 2023, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.

RCEL Financial details

Company Rating
Neutral
Market Cap
355.93M
Income
-30.55M
Revenue
40.85M
Book val./share
2.72
Cash/share
2.62
Dividend
-
Dividend %
-
Employees
126
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-12.05
Forward P/E
-
PEG
-20.14
P/S
9.09
P/B
5.36
P/C
5.58
P/FCF
-14.74
Quick Ratio
5.23
Current Ratio
5.61
Debt / Equity
0.02
LT Debt / Equity
0.02
-
-
EPS (TTM)
-1.24
EPS next Y
-
EPS next Q
-0.63
EPS this Y
-8.55%
EPS next Y
-
EPS next 5Y
63.31%
EPS last 5Y
-3.82%
Revenue last 5Y
95.23%
Revenue Q/Q
11.4%
EPS Q/Q
10.81%
-
-
-
-
SMA20
-12.5%
SMA50
-26.32%
SMA100
-12.5%
Inst Own
30.23%
Inst Trans
1.33%
ROA
-35%
ROE
-38%
ROC
-0.45%
Gross Margin
83%
Oper. Margin
-80%
Profit Margin
-75%
Payout
-
Shs Outstand
25.48M
Shs Float
116.16M
-
-
-
-
Target Price
-
52W Range
4.41-21.7
52W High
-30.33%
52W Low
+265.75%
RSI
42
Rel Volume
0.23
Avg Volume
229.99K
Volume
52.09K
Perf Week
5.56%
Perf Month
-7.64%
Perf Quarter
-8.05%
Perf Half Y
8.13%
-
-
-
-
Beta
1.25113
-
-
Volatility
0.32%, 0.89%
Prev Close
0.34%
Price
14.63
Change
1.39%

RCEL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-06-302020-06-302021-06-302021-06-30 2022-12-31
Revenue per share
0.130.340.71.291.38
Net income per share
-1.3-1.53-2.07-1.17-1.07
Operating cash flow per share
-1.29-1.2-1.12-1.14-0.76
Free cash flow per share
-1.33-1.25-1.16-1.19-0.78
Cash per share
1.171.263.634.883.17
Book value per share
1.51.33.575.13.39
Tangible book value per share
1.51.283.555.083.37
Share holders equity per share
1.51.33.575.13.39
Interest debt per share
0.0100.10.040.04
Market cap
68.01M709.12M416.37M465.28M165M
Enterprise value
57.22M688.86M344.65M355.41M147.76M
P/E ratio
-5.62-28.8-9.91-17.5-6.19
Price to sales ratio
56.04131.4129.1915.924.79
POCF ratio
-5.66-36.84-18.3-17.96-8.64
PFCF ratio
-5.49-35.29-17.65-17.18-8.41
P/B Ratio
4.8633.995.754.021.95
PTB ratio
4.8633.995.754.021.95
EV to sales
47.15127.6524.1612.164.29
Enterprise value over EBITDA
-4.36-27.86-8.3-13.4-5.67
EV to operating cash flow
-4.76-35.79-15.15-13.72-7.74
EV to free cash flow
-4.62-34.28-14.61-13.13-7.53
Earnings yield
-0.18-0.03-0.1-0.06-0.16
Free cash flow yield
-0.18-0.03-0.06-0.06-0.12
Debt to equity
0.0100.030.010.01
Debt to assets
0.0100.020.010.01
Net debt to EBITDA
0.820.821.734.140.66
Current ratio
5.755.510.1716.428.18
Interest coverage
-672.47-934.69-1.29K-1.21K-1.72K
Income quality
0.990.780.540.970.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.632.352.430.770.68
Research and developement to revenue
5.241.860.590.510.4
Intangibles to total assets
00.01000
Capex to operating cash flow
0.030.040.040.050.03
Capex to revenue
-0.3-0.16-0.06-0.04-0.02
Capex to depreciation
-3.47-3.2-1.82-1.64-0.92
Stock based compensation to revenue
00.361.160.190.2
Graham number
6.626.6912.911.69.02
ROIC
-0.85-1.17-0.56-0.23-0.32
Return on tangible assets
-0.72-0.97-0.51-0.21-0.27
Graham Net
1.221.083.254.732.82
Working capital
13.54M19.82M70.68M113.94M76.77M
Tangible asset value
13.98M20.64M72.04M115.18M84.28M
Net current asset value
13.44M19.35M68.33M111.48M73.93M
Invested capital
0.0100.030.010.01
Average receivables
2.81M3.05M2.26M4.92M6.18M
Average payables
2.19M3.25M4.14M3.73M3.06M
Average inventory
823.16K794.93K932.9K1.39M1.89M
Days sales outstanding
1.21K141.1762.2492.4452.6
Days payables outstanding
1.81K1.21K531.97191.43181.38
Days of inventory on hand
598.43227.4138.12101.05128.39
Receivables turnover
0.32.595.863.956.94
Payables turnover
0.20.30.691.912.01
Inventory turnover
0.611.612.643.612.84
ROE
-0.87-1.18-0.58-0.23-0.31
Capex per share
-0.04-0.05-0.04-0.05-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.330.360.420.420.47
Net income per share
-0.25-0.22-0.24-0.37-0.41
Operating cash flow per share
-0.14-0.11-0.15-0.36-0.36
Free cash flow per share
-0.15-0.12-0.16-0.37-0.37
Cash per share
3.383.373.52.912.62
Book value per share
3.713.523.743.082.72
Tangible book value per share
3.693.53.723.062.7
Share holders equity per share
3.713.523.743.082.72
Interest debt per share
0.020.040.040.070.07
Market cap
118.61M131.79M149.65M352.07M429.33M
Enterprise value
84.41M109.29M132.4M325.9M392.89M
P/E ratio
-4.74-5.9-6.99-9.55-10.34
Price to sales ratio
14.2314.4915.8333.3736.53
POCF ratio
-33.82-47.46-43.55-38.8-47.17
PFCF ratio
-31.71-45.41-42.44-37.56-45.65
P/B Ratio
1.281.51.774.546.25
PTB ratio
1.281.51.774.546.25
EV to sales
10.1312.021430.8933.43
Enterprise value over EBITDA
-13.8-20.09-25.5-36.01-37.91
EV to operating cash flow
-24.07-39.36-38.53-35.92-43.17
EV to free cash flow
-22.56-37.66-37.55-34.77-41.77
Earnings yield
-0.05-0.04-0.04-0.03-0.02
Free cash flow yield
-0.03-0.02-0.02-0.03-0.02
Debt to equity
0.010.010.010.020.02
Debt to assets
0.010.010.010.020.02
Net debt to EBITDA
5.594.133.322.893.52
Current ratio
11.649.648.187.215.61
Interest coverage
-1.59K-958-984.67-2.48K-1.6K
Income quality
0.560.50.640.980.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.660.550.560.790.52
Research and developement to revenue
0.370.420.360.430.43
Intangibles to total assets
00000.01
Capex to operating cash flow
0.070.050.030.030.03
Capex to revenue
-0.03-0.01-0.01-0.03-0.03
Capex to depreciation
-1.71-0.91-0.69-2.23-2.08
Stock based compensation to revenue
0.170.160.130.250.1
Graham number
4.574.214.465.035.02
ROIC
-0.07-0.06-0.07-0.12-0.16
Return on tangible assets
-0.06-0.06-0.05-0.1-0.12
Graham Net
3.153.063.112.532.16
Working capital
83.92M82.21M76.77M71.28M63.69M
Tangible asset value
92.13M87.54M84.28M77.1M68.19M
Net current asset value
81.7M79.77M73.93M67.7M59.81M
Invested capital
0.010.010.010.020.02
Average receivables
4.28M4.45M4.73M5.07M5.69M
Average payables
2.45M3.05M3.3M3.38M3.79M
Average inventory
1.91M1.99M2.04M2.47M2.93M
Days sales outstanding
47.3744.6247.2144.247.45
Days payables outstanding
162.01211.65200.58202.57156.68
Days of inventory on hand
131.3115.29141.98151.76124.87
Receivables turnover
1.92.021.912.041.9
Payables turnover
0.560.430.450.440.57
Inventory turnover
0.690.780.630.590.72
ROE
-0.07-0.06-0.06-0.12-0.15
Capex per share
-0.0100-0.01-0.01

RCEL Frequently Asked Questions

What is AVITA Medical, Inc. stock symbol ?

AVITA Medical, Inc. is a US stock , located in Valencia of Ca and trading under the symbol RCEL

What is AVITA Medical, Inc. stock quote today ?

AVITA Medical, Inc. stock price is $14.63 today.

Is AVITA Medical, Inc. stock public?

Yes, AVITA Medical, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap